{"BSX": {"Ticker": "BSX", "Company": "Boston Scientific", "Sector": "Health Care", "Updated": "2022-12-22", "Rating": [{"Date": "2022-12-22", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Neutral", "Target_Change": "$52"}, {"Date": "2022-12-20", "Rating": "Resumed", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$54"}, {"Date": "2022-10-18", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$49"}, {"Date": "2022-10-12", "Rating": "Initiated", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$50"}], "Score": 1.5, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "A", "Analists": ["Barclays", "Citigroup", "Mizuho", "Jefferies"], "Price_Target": 51.25}, "COO": {"Ticker": "COO", "Company": "The Cooper Companies", "Sector": "Health Care", "Updated": "2022-12-22", "Rating": [{"Date": "2022-12-22", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Buy", "Target_Change": "$375"}, {"Date": "2022-11-30", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Neutral to Outperform", "Target_Change": "$345 to $375"}, {"Date": "2022-10-12", "Rating": "Downgrade", "Organization": "Jefferies", "Rating_Change": "Buy to Hold", "Target_Change": "$400 to $295"}], "Score": 1.0, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Jefferies", "Mizuho", "Robert W. Baird"], "Price_Target": 348.33}}